Feinstein Institute for Medical Research   Report issue

Contributed to NME Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Manhasset NY United States (1991)

Organization Overview

First Clinical Trial
2006
NCT00301418
First Marketed Drug
2005
fludeoxyglucose f-18
First NDA Approval
2019
fluorodopa (fluorodopa F18)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Adrianna Vlachos | FEINSTEIN | Feinstein Institute | Feinstein Institute for Medical Research | Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases | Feinstein Institute for Medical Research North Shore-Long Island Jewish Health System | Feinstein Institute for Medical Research NS-LIJ Health System | Marc L Gordon, MD | THE FEINSTEIN INST | The Feinstein Institute for Medical Research | The Feinstein Institute for Medical Research NS-LIJ Health System

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenal Hyperplasia, Congenital (Phase 2)

Adrenocortical Hyperfunction (Phase 2)

Adrenogenital Syndrome (Phase 2)

Alzheimer Disease (Phase 2)

Anemia (Phase 2)

Anemia, Diamond-Blackfan (Phase 2)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Astrocytoma (Phase 2)

Ear Diseases (Phase 2)

Glioblastoma (Phase 2)

Huntington Disease (Phase 2)

Hyperplasia (Phase 2)

Labyrinth Diseases (Phase 2)

Labyrinthitis (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lupus Nephritis (Phase 2)

Metabolic Syndrome (Phase 4)

Nephritis (Phase 2)

Neurilemmoma (Phase 1)

Neuroma, Acoustic (Phase 1)

Obesity, Abdominal (Phase 4)

Parkinson Disease (Phase 1)

Red-Cell Aplasia, Pure (Phase 2)

Syndrome (Phase 4)

Telangiectasia, Hereditary Hemorrhagic (Phase 2)

Telangiectasis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 32